MedTrace Logo

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

NCT02693093 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2022-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of NI-03.

Conditions

  • Chronic Pancreatitis

Interventions

DRUG

NI-03

DRUG

Placebo

Sponsors & Collaborators

  • Kangen Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Phiip Hart, MD · OSU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-24
Primary Completion
2021-09-30
Completion
2021-12-30

Countries

  • United States
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02693093 on ClinicalTrials.gov